Breakdown | ||||
Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
293.96B | 262.17B | 238.59B | 213.99B | 189.89B | Gross Profit |
9.91B | 8.96B | 8.33B | 6.77B | 5.20B | EBIT |
2.18B | 2.34B | 2.37B | 2.35B | -5.14B | EBITDA |
3.25B | 3.41B | 3.11B | 2.91B | -4.75B | Net Income Common Stockholders |
1.51B | 1.75B | 1.70B | 1.54B | -3.41B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
3.13B | 2.59B | 3.39B | 2.55B | 4.60B | Total Assets |
67.10B | 62.56B | 56.56B | 57.34B | 43.95B | Total Debt |
4.39B | 4.79B | 5.70B | 6.68B | 4.12B | Net Debt |
1.26B | 2.20B | 2.31B | 4.14B | -478.23M | Total Liabilities |
66.31B | 61.89B | 56.49B | 56.75B | 44.79B | Stockholders Equity |
645.94M | 666.29M | -289.78M | 223.35M | -839.64M |
Cash Flow | Free Cash Flow | |||
3.00B | 3.45B | 2.21B | 2.23B | 1.84B | Operating Cash Flow |
3.48B | 3.91B | 2.70B | 2.67B | 2.21B | Investing Cash Flow |
-618.10M | -2.60B | -368.44M | -6.14B | -379.87M | Financing Cash Flow |
-2.33B | -2.22B | -1.75B | 1.95B | -603.62M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $88.58B | 32.39 | 51.23% | 0.39% | 14.29% | -1.20% | |
76 Outperform | $87.75B | 19.01 | 6.07% | 3.99% | 4.02% | -43.51% | |
74 Outperform | $31.68B | 10.22 | 12.59% | ― | 8.85% | 33.30% | |
73 Outperform | $56.75B | 41.64 | 245.32% | 0.72% | 11.64% | -23.54% | |
66 Neutral | $35.16B | 27.17 | -43.80% | 1.43% | 2.85% | 110.82% | |
65 Neutral | $79.89B | 24.69 | 19.11% | 3.84% | 6.28% | -47.11% | |
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% |
On March 10, 2025, Cencora, Inc. executives will present at the Leerink Partners Global Healthcare Conference, where they will update their fiscal year 2025 financial guidance. The adjusted diluted earnings per share for fiscal 2025 is now projected to be between $15.30 and $15.60, reflecting positive momentum in their core U.S. Healthcare Solutions segment.
On February 5, 2025, Cencora reported a revenue increase of 12.8% year-over-year to $81.5 billion for the first quarter of fiscal 2025. The adjusted diluted earnings per share rose by 13.7% to $3.73. The company has raised its adjusted diluted EPS guidance range for fiscal 2025 and emphasized its strategic focus on specialty services following the acquisition of Retina Consultants of America. Despite a decrease in GAAP diluted EPS and operating income, Cencora highlighted its customer-centric approach and execution of its pharmaceutical strategy as key drivers for maintaining its market leadership.